Literature DB >> 24917535

Severity of manifestations in tuberous sclerosis complex in relation to genotype.

Sanjeev V Kothare1, Kanwaljit Singh, Jason R Chalifoux, Brigid A Staley, Howard L Weiner, Kimberly Menzer, Orrin Devinsky.   

Abstract

OBJECTIVE: Patients with tuberous sclerosis complex (TSC) commonly present with significant neurologic deficits, including seizures, autism, and intellectual disability. Previous evidence suggests that the TSC2 mutation genotype may be associated with a more severe disease phenotype. This study evaluates the association of the TSC1 and TSC2 genotype with patient and disease characteristics in a retrospective review of a large TSC Natural History Database consisting of 919 patients with TSC.
METHODS: Univariate logistic regression was conducted to evaluate the association of the TSC1 and TSC2 gene mutations with patient and disease characteristics.
RESULTS: As compared to patients with the TSC1 mutation, patients with the TSC2 mutation were younger (p = 0.02), more likely to have partial epilepsy (odds ratio (OR) 1.74, p = 0.0015), complex partial seizures (OR 2.03, p = 0.02), infantile spasms (IS) (OR 1.67, p = 0.01), subependymal giant-cell astrocytomas (SEGAs) (OR 1.64, p = 0.01), and intellectual disability (OR 2.90, p = 0.0002). SIGNIFICANCE: The clinical presentation of TSC is highly variable and not well understood. Our findings confirm and supplement existing literature that TSC2 mutation is likely to be associated with a more severe, earlier presenting TSC phenotype, including infantile spasms. Wiley Periodicals, Inc.
© 2014 International League Against Epilepsy.

Entities:  

Keywords:  Epilepsy; TSC mutations; Tuberous sclerosis complex

Mesh:

Substances:

Year:  2014        PMID: 24917535     DOI: 10.1111/epi.12680

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  29 in total

1.  [Chinese expert consensus on surgical treatment of tuberous sclerosis complex-related epilepsy].

Authors: 
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-08

Review 2.  A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

Authors:  Petrus J de Vries; Lucy Wilde; Magdalena C de Vries; Romina Moavero; Deborah A Pearson; Paolo Curatolo
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-08-16       Impact factor: 3.908

3.  Genotype and brain pathology phenotype in children with tuberous sclerosis complex.

Authors:  Iris E Overwater; Rob Swenker; Emma L van der Ende; Kimberley Bm Hanemaayer; Marianne Hoogeveen-Westerveld; Agnies M van Eeghen; Maarten H Lequin; Ans Mw van den Ouweland; Henriëtte A Moll; Mark Nellist; Marie-Claire Y de Wit
Journal:  Eur J Hum Genet       Date:  2016-07-13       Impact factor: 4.246

4.  Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.

Authors:  Marian E Williams; Deborah A Pearson; Jamie K Capal; Anna W Byars; Donna S Murray; Robin Kissinger; Sarah E O'Kelley; Ellen Hanson; Nicole M Bing; Bridget Kent; Joyce Y Wu; Hope Northrup; E Martina Bebin; Mustafa Sahin; Darcy Krueger
Journal:  Am Psychol       Date:  2019-04

5.  Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex.

Authors:  Anna Jeong; Jo Anne Nakagawa; Michael Wong
Journal:  J Child Neurol       Date:  2017-12       Impact factor: 1.987

Review 6.  Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex.

Authors:  Emma van der Poest Clement; Floor E Jansen; Kees P J Braun; Jurriaan M Peters
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

Review 7.  Cerebellar Development and Autism Spectrum Disorder in Tuberous Sclerosis Complex.

Authors:  Maria Sundberg; Mustafa Sahin
Journal:  J Child Neurol       Date:  2015-08-24       Impact factor: 1.987

Review 8.  Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literature.

Authors:  Parisa Mortaji; Katherine T Morris; Von Samedi; Steven Eberhardt; Shawnia Ryan
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

9.  Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming.

Authors:  Laura C Armstrong; Grant Westlake; John P Snow; Bryan Cawthon; Eric Armour; Aaron B Bowman; Kevin C Ess
Journal:  Hum Mol Genet       Date:  2017-12-01       Impact factor: 6.150

10.  Pattern of TSC1 and TSC2 germline mutations in Russian patients with tuberous sclerosis.

Authors:  Evgeny N Suspitsin; Grigoriy A Yanus; Marina Yu Dorofeeva; Tatiana A Ledashcheva; Nataliya V Nikitina; Galina V Buyanova; Elena V Saifullina; Anna P Sokolenko; Evgeny N Imyanitov
Journal:  J Hum Genet       Date:  2018-02-23       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.